New Providence research published in Nature-Precision Oncology finds that in head and neck cancer, researchers found that two specific immune response patterns—called Activation and Infiltration—can better predict who will benefit from immunotherapy. Patients whose tumors showed both patterns responded best to treatment and lived longer. These findings, confirmed in multiple patient groups, suggest using combined biomarkers is more effective than relying on a single one.
Population genetic screening is evolving beyond targeted panels as next-generation sequencing (NGS) technology makes whole genome sequencing (WGS) more efficient and accessible
New research recently published in the New England Journal of Medicine begs the question: Can an AI-based model revolutionize clinical research?
A new study from researchers at Providence, published in Nature NPJ Genomic Medicine, demonstrates how Whole Genome Sequencing (WGS) can transform health care
Genetic testing has moved beyond academic centers to being reflected in clinical guidelines adopted by a growing number of clinicians
A wide variety of medical imaging tools (CT,MRI, pathology etc.) are used in routine medical care, and represent robust datasets for potential biomedical discovery using Artificial Intelligence (AI)
Research from a team led by Brian Piening, PhD, Program Director for Providence Genomics that included colleagues from across Providence as well as collaborators at Illumina and Microsoft
Prevention4ME has identified more than 2600 patients at high risk for cancer who are now being screened differently or receiving NCCN guideline-recommended genetic testing
Providence Genomics and Providence-Swedish Cancer Institute have launched the PREVAIL study,
Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System
This research highlights a new artificial intelligence model that Providence, Microsoft, and the University of Washington used to diagnose cancer.
Everett-based Providence Comprehensive Breast Center is the first program in Providence’s seven-state health system to launch a free, personalized cancer screening and early detection system.
Xenotransplantation—the grating or transplanting of organs or tissues between members of different species
This innovative Artificial Intelligence (AI) technology involves the digitization of traditional glass slides which enables pathologists to access, analyze, and share high-resolution whole-slide image
This study includes authors from Providence Genomics in collaboration with Providence Swedish Cancer Institute.
An estimated 90 percent of individuals with inherited cancer risk do not know they are at risk.
Providence Genomics and EACRI researchers conducted a multi-year study of the impact of removing testing barriers to comprehensive genomic profiling (CGP) for patients with advanced cancers.
Population genetic screening is evolving beyond targeted panels as next-generation sequencing (NGS) technology makes whole genome sequencing (WGS) more efficient and accessible.
This single blood test screens for more than 50 cancers by looking at blood for DNA shed by cancer tumors.
